Acumen Pharmaceuticals Inc expected to post a loss of 52 cents a share - Earnings Preview

Acumen Pharmaceuticals

08/08/2025 16:32

Acumen Pharmaceuticals Inc ABOS.OQ ABOS.O is expected to  show no change in quarterly revenue when it reports  results on August 12 for the period ending June 30 2025

​LSEG's mean analyst estimate for Acumen Pharmaceuticals Inc is for a loss of 52 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 15.3% in the last three months. ​

Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $10.00, about 85.8% above its last closing price of $1.42

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.41
-0.45
-0.48
Missed
-5.7
Dec. 31 2025
-0.48
-0.62
Missed
-29.2
Sep. 30 2024
-0.41
-0.36
-0.50
Missed
-37​
Jun. 30 2024
-0.28
-0.28
-0.34
Missed
-21.4
​​Mar. 31 2024
-0.26
-0.26
-0.25
Beat
3.8
Dec. 31 2023
-0.30
-0.26
-0.28
Missed
-7.7​
Sep. 30 2023
-0.27
-0.27
-0.24
Beat
9.8
Jun. 30 2023
-0.34
-0.35
-0.28
Beat
19.1

This summary was machine generated August 8 at 15:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)